It is critical time in the industry of pharma patents. The decisions handed down (late last year) in the Actavis, Medeva and Lilly cases will have profound implications for pharma patentees. The implementation of the Unified Patent Court continues to raise questions and issues which must be critically addressed. Amendments to UK legislation relating to the Bolar exemption must be evaluated.
The 13th International Forum on Pharma Patent Extensions will address the pressing concerns and issues facing the industry at present. It will bring together eminent in-house counsel from the world’s largest pharma companies and their expert advisors from a range of jurisdictions, including the US, Europe and beyond.
The Forum will provide a critical insight into the significant changes, updates and forecasts. Plus unparalleled learning prospects including, top tips, strategies and tactics to ensure you maximise your opportunities to optimise the life-cycle of your patents and implement the most practical and cost effective procedures.
The diverse and international panellists will address the pressing and newest topics including:
- Understanding the challenges, risks, and opportunities of the proposed Unitary Patent. A careful analysis of the opt in and opt out procedure. What are your options and how should you proceed in the best interests of your organisation
- A crucial analysis of the recent decisions relating to SPC’s. What does this mean for you?
- An examination of the second medical use patents and strategies for enforcement
- Successful patent filing and expiry strategies
Be where your industry will be on 25th and 26th June 2014 and don’t miss out on this unique opportunity to hear from and network with prominent judicial authorities, regulatory experts and industry specialists.
Bina Nanavati, C5
Tel: : +44 (0) 20 7878 6942
Marketing and media support enquiries:
Nathan Denham, C5
Tel: : +44 (0) 20 7878 6928
Business development opportunities:
Evi Kartsouni, C5
Tel: +44 (0) 20 7878 6955